134 related articles for article (PubMed ID: 28062980)
1. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
[TBL] [Abstract][Full Text] [Related]
2. The
Gliniewicz K; Kluźniak W; Wokołorczyk D; Huzarski T; Stempa K; Rudnicka H; Jakubowska A; Szwiec M; Jarkiewicz-Tretyn J; Naczk M; Kluz T; Dębniak T; Gronwald J; Lubiński J; Narod SA; Akbari MR; Cybulski C
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510234
[TBL] [Abstract][Full Text] [Related]
3. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
4. The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.
Liu J; Sieuwerts AM; Look MP; van der Vlugt-Daane M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
PLoS One; 2016; 11(8):e0161731. PubMed ID: 27552096
[TBL] [Abstract][Full Text] [Related]
5. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
[TBL] [Abstract][Full Text] [Related]
6. Genetic Polymorphisms Predisposing the Interleukin 6-Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations.
Liu W; Wu J; Yang F; Ma L; Ni C; Hou X; Wang L; Xu A; Song J; Deng Y; Xian L; Li Z; Wang S; Chen X; Yin J; Han X; Li C; Zhao J; Cao G
Clin Cancer Res; 2019 Sep; 25(18):5525-5536. PubMed ID: 31152021
[TBL] [Abstract][Full Text] [Related]
7. Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Kim SH; Ahn S; Suh KJ; Kim YJ; Park SY; Kang E; Kim EK; Kim IA; Chae S; Choi M; Kim JH
Breast Cancer Res Treat; 2020 Oct; 183(3):697-704. PubMed ID: 32715441
[TBL] [Abstract][Full Text] [Related]
8. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
[TBL] [Abstract][Full Text] [Related]
9. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
[TBL] [Abstract][Full Text] [Related]
10. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
11. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.
Law EK; Sieuwerts AM; LaPara K; Leonard B; Starrett GJ; Molan AM; Temiz NA; Vogel RI; Meijer-van Gelder ME; Sweep FC; Span PN; Foekens JA; Martens JW; Yee D; Harris RS
Sci Adv; 2016 Oct; 2(10):e1601737. PubMed ID: 27730215
[TBL] [Abstract][Full Text] [Related]
12. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
13. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
14. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
[TBL] [Abstract][Full Text] [Related]
15. A germ-line deletion of APOBEC3B does not contribute to subtype-specific childhood acute lymphoblastic leukemia etiology.
Wallace AD; Francis SS; Shao X; de Smith AJ; Walsh KM; Mckean-Cowdin R; Ma X; Dahl G; Barcellos LF; Wiemels JL; Metayer C
Haematologica; 2018 Jan; 103(1):e29-e31. PubMed ID: 29025908
[No Abstract] [Full Text] [Related]
16. APOBEC3B deletion impacts on susceptibility to acquire HIV-1 and its advancement among individuals in western India.
Singh H; Marathe SD; Nain S; Nema V; Ghate MV; Gangakhedkar RR
APMIS; 2016 Oct; 124(10):881-7. PubMed ID: 27522954
[TBL] [Abstract][Full Text] [Related]
17. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
[TBL] [Abstract][Full Text] [Related]
19. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
[TBL] [Abstract][Full Text] [Related]
20. Acute expression of human APOBEC3B in mice results in RNA editing and lethality.
Alonso de la Vega A; Temiz NA; Tasakis R; Somogyi K; Salgueiro L; Zimmer E; Ramos M; Diaz-Jimenez A; Chocarro S; Fernández-Vaquero M; Stefanovska B; Reuveni E; Ben-David U; Stenzinger A; Poth T; Heikenwälder M; Papavasiliou N; Harris RS; Sotillo R
Genome Biol; 2023 Nov; 24(1):267. PubMed ID: 38001542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
